Every one of those 1 sits in a single category, medical-devices. Of the tracked stories, 1 of 1 also mention Astellas Pharma, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jose Carmena
Every one of those 1 sits in a single category, medical-devices. Of the tracked stories, 1 of 1 also mention Astellas Pharma, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Jose Carmena, all published on March 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jose Carmena. Shared-story counts are live from our verified record — not editorial picks.
The founder of Iota Biosciences has been named the keynote speaker for the 2026 Bioelectronic Medicine Forum in New York City. This announcement highlights the growing prominence of 'neural dust' technology and its potential to revolutionize chronic disease management through ultra-miniature bioelectronic implants.